Amaro
Category: AI in Healthcare
An AI-native advertising platform that streamlines the evaluation and improvement of advertising performance, primarily targeting healthcare and life sciences sectors. Amaro was founded in 2022. The company is led by Not publicly available (Acquired). Based in Boston, USA. Team size: N/A. Total funding raised: $7 million. Latest round: Venture round. Key investors include Google Ventures.
- Founded
- 2022
- Headquarters
- Boston, USA
- Team size
- N/A
- Total funding
- $7 million
Value proposition
Uses AI to optimize advertising campaigns and provide actionable insights for performance improvement.
Products and solutions
AI-native advertising platform
Unique value
AI-native approach that automates and enhances advertising performance analysis, going beyond traditional methods.
Target customer
Businesses and advertising agencies in healthcare and life sciences.
Industries served
Healthcare, Life Sciences, Advertising
Technology advantage
Proprietary AI technology tailored for advertising evaluation specifically in healthcare domains.
How they differentiate
Combines AI-driven real-world evidence generation with a modern advertising infrastructure focusing on healthcare professionals.
Main competitors
Aetion, Flatiron Health, IQVIA
Key partnerships
Google Ventures, OpenEvidence
Notable customers
Not publicly available
Major milestones
Backed by Google Ventures, Developed AI-native advertising and real-world evidence platform, Acquired by OpenEvidence
Growth metrics
Not publicly available
Market positioning
Positioned as the AI-powered real-world evidence provider for biopharma, payers, and regulators, now integrated with OpenEvidence.
Geographic focus
United States, primarily Boston biotech and pharmaceutical hub.
Patents and IP
Not publicly disclosed
About Not publicly available (Acquired)
Amaro was founded by a team with expertise in healthcare, AI, and venture capital. Key founders have leadership and academic roles in AI and biomedical informatics.
Official website: https://www.openevidence.com/